Perspective Therapeutics (CATX) Interest Coverage Ratio Growth (1y) (2011 - 2026)
Powered by 
Analysis
Perspective Therapeutics (CATX) Interest Coverage Ratio Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 176.09% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | -103.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -103.99% |
| Mar 31, 2026 | -57.91% |
| Jun 30, 2025 | 67.42% |
| Mar 31, 2025 | 61.97% |
| Dec 31, 2024 | 226.66% |
| Sep 30, 2024 | 61.22% |
| Jun 30, 2024 | -65.30% |
| Mar 31, 2024 | 17.30% |
| Jun 30, 2016 | -3,621.66% |
| Sep 30, 2015 | -241.33% |
| Jun 30, 2015 | 103.02% |
| Sep 30, 2014 | 79.80% |
| Jun 30, 2014 | 97.69% |
| Sep 30, 2013 | 99.11% |
| Jun 30, 2013 | -6,007,902.21% |
| Sep 30, 2012 | -1,495.79% |
| Jun 30, 2012 | 48.77% |
| Mar 31, 2012 | -5,783.71% |
| Dec 31, 2011 | -507.25% |
| Sep 30, 2011 | -5,926.23% |